Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Read More…
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone978-671-8001
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$343.37 million
Profitability
Miscellaneous
Employees488
Next Earnings Date8/7/2019 (Estimated)
OptionableOptionable
Lantheus (NASDAQ:LNTH) Frequently Asked Questions
What is Lantheus' stock symbol?
Lantheus trades on the NASDAQ under the ticker symbol "LNTH."
How were Lantheus' earnings last quarter?
Lantheus Holdings Inc (NASDAQ:LNTH) issued its earnings results on Tuesday, April, 30th. The medical equipment provider reported $0.28 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.25 by $0.03. The medical equipment provider earned $86.51 million during the quarter, compared to the consensus estimate of $86.80 million. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. View Lantheus' Earnings History.
When is Lantheus' next earnings date?
What guidance has Lantheus issued on next quarter's earnings?
Lantheus issued an update on its FY 2019 earnings guidance on Tuesday, April, 30th. The company provided earnings per share guidance of $1.14-1.17 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.16. The company issued revenue guidance of $357.967-363.118 million, compared to the consensus revenue estimate of $360.74 million.
What price target have analysts set for LNTH?
2 Wall Street analysts have issued 12-month target prices for Lantheus' shares. Their predictions range from $20.00 to $21.00. On average, they anticipate Lantheus' share price to reach $20.50 in the next year. This suggests that the stock has a possible downside of 25.7%. View Analyst Price Targets for Lantheus.
What is the consensus analysts' recommendation for Lantheus?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.
Has Lantheus been receiving favorable news coverage?
Media stories about LNTH stock have been trending neutral this week, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Lantheus earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned news stories about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Lantheus.
Are investors shorting Lantheus?
Lantheus saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 714,800 shares, an increase of 12.4% from the April 30th total of 635,800 shares. Based on an average daily trading volume, of 375,500 shares, the days-to-cover ratio is presently 1.9 days. Approximately 1.9% of the company's shares are short sold. View Lantheus' Current Options Chain.
Who are some of Lantheus' key competitors?
Some companies that are related to Lantheus include Neogen (NEOG), Immunomedics (IMMU), Quidel (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Quotient (QTNT), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), ImmuCell (ICCC), Riot Blockchain (RIOT), Trinity Biotech (TRIB) and Celldex Therapeutics (CLDX).
What other stocks do shareholders of Lantheus own?
Who are Lantheus' key executives?
Lantheus' management team includes the folowing people:
- Ms. Mary Anne Heino, CEO, Pres & Director (Age 59)
- Mr. Robert J. Marshall Jr., CFO & Treasurer (Age 52)
- Mr. Michael P. Duffy, Sr. VP of Law & Public Policy, Gen. Counsel and Sec. (Age 58)
- Dr. Cesare Orlandi, Chief Medical Officer (Age 69)
- Mr. John J. Bolla, Chief Operating Officer (Age 49)
When did Lantheus IPO?
(LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.
Who are Lantheus' major shareholders?
Lantheus' stock is owned by a number of of institutional and retail investors. Top institutional investors include LSV Asset Management (4.21%), Vaughan Nelson Investment Management L.P. (4.09%), Peregrine Capital Management LLC (1.94%), JPMorgan Chase & Co. (1.88%), Lazard Asset Management LLC (0.84%) and Connor Clark & Lunn Investment Management Ltd. (0.63%). Company insiders that own Lantheus stock include A Frederick Robertson, Avista Capital Partners Gp, Ll, Brian A Markison, Cesare Orlandi, David F Burgstahler, Derace L Schaffer, John J Bolla, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Sam R Leno and Timothy G Healey. View Institutional Ownership Trends for Lantheus.
Which major investors are selling Lantheus stock?
LNTH stock was sold by a variety of institutional investors in the last quarter, including AlphaOne Investment Services LLC, Gabelli Funds LLC, Royce & Associates LP, Peregrine Capital Management LLC, IndexIQ Advisors LLC, Cadence Capital Management LLC, Gamco Investors INC. ET AL and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy and Sam R Leno. View Insider Buying and Selling for Lantheus.
Which major investors are buying Lantheus stock?
LNTH stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, JPMorgan Chase & Co., CIBC World Markets Inc., Vaughan Nelson Investment Management L.P., EAM Global Investors LLC, Assenagon Asset Management S.A., Cambridge Investment Research Advisors Inc. and Spark Investment Management LLC. View Insider Buying and Selling for Lantheus.
How do I buy shares of Lantheus?
Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lantheus' stock price today?
One share of LNTH stock can currently be purchased for approximately $27.58.
How big of a company is Lantheus?
Lantheus has a market capitalization of $1.07 billion and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe.View Additional Information About Lantheus.
What is Lantheus' official website?
How can I contact Lantheus?
Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]
MarketBeat Community Rating for Lantheus (NASDAQ LNTH)
MarketBeat's community ratings are surveys of what our community members think about Lantheus and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
